HROW (Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued
HROW (Pharmaceuticals) trades at a blended P/E of 554.2, about 1172% above its historical normal valuation, with a forward growth estimate of 429.6% and a PEG of 1.29. Analysts' one-year estimates have been hit 9% of the time.
Valuation flags
- Overvalued by 1172%
Frequently asked questions
Is HROW overvalued?
At a blended P/E of 554.2 versus its historical normal P/E of 43.6, HROW trades about 1172% above its typical valuation, with a PEG of 1.29 on 429.6% forward growth. tickerseer currently rates it significantly overvalued.
What is HROW's fair value and PEG?
HROW trades at a blended P/E of 554.2 against a historical normal P/E of 43.6, a PEG of 1.29, and a forward growth estimate of 429.6%.
Has tickerseer's rating of HROW changed?
tickerseer's rating has been significantly overvalued since 2026-08-07.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.